Therapeutic Advances in Hematology

Papers
(The TQCC of Therapeutic Advances in Hematology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias30
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib27
Venetoclax-containing regimens in acute myeloid leukemia24
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies23
Bortezomib in autoimmune hemolytic anemia and beyond22
Current evidence and the emerging role of eltrombopag in severe aplastic anemia21
Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review19
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria19
Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy17
Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin)16
Clinical features ofDDX41mutation-related diseases: a systematic review with individual patient data15
Primary central nervous system lymphoma in the United States, 1975–201715
International consensus recommendations on the management of people with haemophilia B14
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia14
Current and emerging treatment options in primary mediastinal B-cell lymphoma13
Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor13
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia12
The potential of pirtobrutinib in multiple B-cell malignancies12
Current state of CAR-T therapy for T-cell malignancies12
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective12
Advances in therapeutic options for newly diagnosed, high-risk AML patients11
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria11
MYD88L265Pand CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy11
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma11
The role of carfilzomib in relapsed/refractory multiple myeloma11
Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications11
Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study10
Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers10
The role of tazemetostat in relapsed/refractory follicular lymphoma10
Mantle cell lymphoma management trends and novel agents: where are we going?10
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma10
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy9
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)9
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data9
Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma9
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)8
Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation8
Emicizumab in acquired haemophilia A: about two clinical cases and literature review8
Safety and efficacy of a single total dose infusion (1020 mg) of ferumoxytol8
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma8
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma8
Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia8
Acute myeloid leukemia with CPSF6–RARG fusion resembling acute promyelocytic leukemia with extramedullary infiltration8
Update on the role of copanlisib in hematologic malignancies7
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 109/L to <100 × 109/L) at baseline: the final analysis of EXPAND7
The use of tafasitamab in diffuse large B-cell lymphoma7
Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-int7
0.020699024200439